Hot Stocks
|
The company said,… The company said, "We anticipate spending approximately $46M in 2022, which includes $13M for corporate general and administrative costs; $3M for withholding taxes on PSUs and other working capital; and $30M to fund our share of expenditures at the Donlin Gold project, including: $17M for the 2022 drill program, approximately 34,000 meters of core drilling; grid drilling, mineralization continuity and geologic structural controls in three areas of the deposit; In-pit and below-pit exploration; platform mapping to confirm mineralization continuity and key geological controls in representative areas of the deposit. $9M for external affairs, permitting, environmental, land and legal activities, and $4M for project planning and fieldwork, dam and water structures, metallurgical testing, mining studies, hydrogeology and geochemistry, and infrastructure planning." ShowHide Related Items >><< - 02/28/22
- Dolin Gold announces assay results for 2021 drill program
- 02/14/22
- Paulson buys Cerner, exits Pretium in Q4
- 12/01/21
- NovaGold, Barrick Gold agree on next steps to advance Donlin Gold
- 11/15/21
- Paulson & Co. exits Dish, boosts Didi Global in Q3
- 02/07/22 RBC Capital
- NovaGold assumed with a Sector Perform at RBC Capital
- 04/05/22
- NovaGold reports Q1 EPS (3c) vs. (2c) a year ago.
- 11/22/21
- Fly Insider: Strategic Education, Vicor among week's notable insider trades
- 04/05/22
- NovaGold options imply 3.3% move in share price post-earnings
|
Hot Stocks
|
Donlin Gold is pleased to… Donlin Gold is pleased to report the release of the final set of assay results from the 2021 drill program. Comprehensive 79-hole, 24,264-meter 2021 drill program produced multiple high-grade gold intercepts. The results support the existing global resource estimate, the recent modelling concepts, and strategic mine planning work; With extensive communication and the application of health and safety protocols, COVID-19 cases at site during 2021 were minimal and there were no lost-time incidents; With the largest project budget in more than a decade, the owners have a plan in place to advance the Donlin Gold project up the value chain in 2022 and position the project to be able to proceed with the preparation of an updated feasibility study, subject to Donlin Gold LLC Board approval; Donlin Gold partnered with local communities in 2021 to provide support and resources in health and safety, environmental management, training and education, as well as cultural initiatives in the Yukon-Kuskokwim region; Additional State permits for the project were received at the end of 2021 - the Alaska Department of Fish and Game issued two Special Area Permits required for pipeline facilities. In December 2021, the Alaska Department of Environmental Conservation approved a third extension of the air quality permit. ShowHide Related Items >><< - 02/14/22
- Paulson buys Cerner, exits Pretium in Q4
- 12/01/21
- NovaGold, Barrick Gold agree on next steps to advance Donlin Gold
- 11/15/21
- Paulson & Co. exits Dish, boosts Didi Global in Q3
- 02/17/22
- McEwen Copper appoints Michael Meding as VP, Andes Corporacion Minera
- 02/16/22
- Barrick Gold announces $1B share repurchase plan
- 02/16/22
- Barrick Gold increases quarterly dividend to10c per share
- 02/07/22
- Barrick, Latin Metals enter earn-in agreement for projects in Argentina
- 02/07/22 RBC Capital
- NovaGold assumed with a Sector Perform at RBC Capital
- 12/15/21 Canaccord
- Great Bear Resources downgraded to Hold from Speculative Buy at Canaccord
- 11/17/21 Canaccord
- Barrick Gold price target lowered to C$31 from C$32 at Canaccord
- 11/08/21 Stifel
- Barrick Gold price target lowered to C$41 from C$42 at Stifel
- 10/15/21 Stifel
- Barrick Gold price target lowered to C$42 from C$42.50 at Stifel
- 02/16/22
- Barrick Gold reports Q4 adjusted EPS 35c, consensus 31c
- 11/04/21
- Barrick Gold reports Q3 adjusted EPS 21c, consensus 31c
- 11/22/21
- Fly Insider: Strategic Education, Vicor among week's notable insider trades
- 12/29/21
- Wall Street in Fives - Must Read Lists at Midday
- 09/29/21
- NovaGold options imply 6.2% move in share price post-earnings
- 02/25/22
- Downside Put buyer in Barrick Gold
- 02/24/22
- Barrick Gold call volume above normal and directionally bullish
- 02/18/22
- Notable open interest changes for February 18th
- 02/16/22
- Unusually active option classes on open February 16th
|
Hot Stocks
|
John Paulson's… John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of December 31, 2021. The fund's four new buys during the fourth quarter included, by size of position, Cerner (CERN), KraneShares CSI China Internet ETF (KWEB), and Tellurian (TELL). Paulson exited five positions during the quarter, including by size of previous position Pretium Resources (PVG) and Viatris (VTRS). The fund increased its stake in two holdings, namely SSR Mining (SSRM) and Pacira Biosciences (PCRX). Paulson reduced its stake in four holdings, including by size of previous position BrightSphere (BSIG), DiDi Global (DIDI), Horizon Therapeutics (HZNP), and Thryv Holdings (THRY). The fund's top holdings as of December 31, in order of size, were Bausch Health (BHC), Horizon Therapeutics, BrightSphere, Novagold Resources (NG), and AngloGold Ashanti (AU). ShowHide Related Items >><< - 02/03/22
- Viatris receives FDA approval for ANDA for generic Restasis
- 02/02/22
- FDA approves first generic of AbbVie's Restasis
- 02/02/22
- Viatris' Mylan granted approval for first generic of AbbVie's Restasis
- 01/20/22
- U.S. appeals court asks Mylan to respond to Biogen request for patent rehearing
- 11/24/21
- Thryv Holdings to replace Echo Global in S&P 600 at open on 11/24
- 11/16/21
- Thryv Holdings CEO and President Joe Walsh buys 45K shares at $35.50 per share
- 11/09/21
- Thryv Holdings to launch real-time centralized inbox
- 10/22/21
- Tellurian to transfer listing of common stock to NYSE American from Nasdaq
- 01/31/22
- SSR Mining intends to increase 2022 base dividend by 40%
- 01/31/22
- SSR Mining sees 2022 production of 700,000-780,000 gold equivalent ounces
- 01/31/22
- SSR Mining reports 2021 production of 794,456 gold equivalent ounces
- 01/28/22
- SSR Mining announces fatal vehicle accident on road to Chinchillas mine
- 01/26/22
- Pretium Resources gets final approval for acquisition by Newcrest Mining
- 01/20/22
- Pretium announces shareholder approval of Newcrest arrangement
- 11/08/21
- Newcrest Mining to acquire Pretium Resources for C$18.50 per share
- 09/13/21
- Pretium says resource expansion drilling continues to intersect high-grade gold
- 02/09/22
- FDA issues draft guidance on developing non-opioid analgesics
- 01/07/22
- Pacira reported Q4 Exparel revenue $139.9M vs. $125.3M last year
- 12/09/21
- Pacira announces closing of $375M five-year Term Loan B
- 12/07/21
- Pacira reports preliminary sales of $48M for November
- 12/01/21
- NovaGold, Barrick Gold agree on next steps to advance Donlin Gold
HZNP Horizon Therapeutics - 01/24/22
- Horizon Therapeutics enrolls first patient in HZN-825 trial
- 01/10/22
- Horizon Therapeutics submits sBLA for concomitant use of KRYSTEXXA in gout
- 01/06/22
- Horizon Therapeutics to be tenant at Alexandria Center in Maryland
- 12/16/21
- Alpine Immune Sciences, Horizon Therapeutics enter exclusive license agreement
DIDI Symbol changed to DIDIY - 12/31/21
- Didi falls -8.0%
- 12/30/21
- Didi appoints Yi Zhang to Board as Daniel Yong Zhang steps down
- 12/03/21
- Didi falls -17.3%
- 12/02/21
- Didi says board authorized procedures to delist from NYSE
- 02/14/22
- Starboard Value adds GoDaddy, boosts Huntsman in Q4
- 02/11/22
- Soros Fund buys Rivian, exits Coupang in Q4
- 12/20/21
- Cerner trading resumes
- 12/20/21
- Oracle confirms agreement to acquire Cerner for $95.00 per share
- 11/15/21
- Paulson & Co. exits Dish, boosts Didi Global in Q3
- 08/16/21
- Paulson buys Bally's, cuts Dish Network in Q2
- 02/14/22
- Icahn boosts Xerox, cuts Delek in Q4
- 01/20/22
- Bausch Health: Dr. Yehia Hashad to join Bausch + Lomb as Chief Medical Officer
- 12/06/21
- Bausch Health receives AMPA seal of approval
- 01/18/22
- Corvus Gold, AngloGold Ashanti complete acquisition
- 11/30/21
- AngloGold Ashanti rises 6.3%
- 11/30/21
- AngloGold Ashanti rises 6.1%
- 09/13/21
- AngloGold Ashanti to acquire Corvus for C$4.10 per share in cash
- 01/06/22 Monness Crespi
- Oracle selloff creates 'attractive buying opportunity,' says Monness Crespi
- 12/21/21 KeyBanc
- Cerner downgraded to Sector Weight from Overweight at KeyBanc
- 12/21/21 Deutsche Bank
- Oracle investors will come to appreciate Cerner deal, says Deutsche Bank
- 12/21/21 KeyBanc
- KeyBanc downgrades Oracle, calls Cerner deal non-strategic
- 07/08/21 B. Riley
- B. Riley starts Tellurian with Buy on liquefied natural gas growth
- 07/08/21 B. Riley
- Tellurian initiated with a Buy at B. Riley
- 06/22/21 Roth Capital
- Tellurian pipeline could lead to reduced emissions, says Roth Capital
- 06/08/21 Evercore ISI
- Tellurian upgraded to Outperform from In Line at Evercore ISI
- 11/15/21 Canaccord
- Pretium Resources downgraded to Hold from Buy at Canaccord
- 11/10/21 Canaccord
- Pretium Resources price target raised to C$18.50 from C$15.50 at Canaccord
- 11/10/21 CIBC
- Pretium Resources price target raised to C$18.50 from C$14.50 at CIBC
- 11/09/21 National Bank
- Pretium Resources downgraded to Tender from Outperform at National Bank
- 12/09/21 Evercore ISI
- Evercore 'conceptually' could understand a Viatris biosimilars deal with Biocon
- 06/15/21 Citi
- Viatris initiated with a Neutral at Citi
- 04/06/21 RBC Capital
- Viatris transferred with an Outperform at RBC Capital
- 03/25/21 Piper Sandler
- Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
- 02/04/22 National Bank
- SSR Mining price target lowered to C$27.50 from C$28.50 at National Bank
- 02/01/22 Canaccord
- SSR Mining price target lowered to C$27 from C$28 at Canaccord
- 01/11/22 Scotiabank
- SSR Mining price target lowered to C$31 from C$38.50 at Scotiabank
- 01/07/22 National Bank
- SSR Mining price target lowered to C$28.50 from C$32 at National Bank
- 01/19/22 Barclays
- Pacira price target raised to $96 from $92 at Barclays
- 01/07/22 H.C. Wainwright
- Pacira reported 'solid' preliminary Q4 sales, says H.C. Wainwright
- 01/04/22 Northland
- Pacira price target raised to $61 from $57 at Northland
- 01/03/22 JPMorgan
- Pacira resumed with an Overweight at JPMorgan
- 12/14/21 Morgan Stanley
- BrightSphere downgraded at Morgan Stanley on more balanced risk/reward
- 12/14/21 Morgan Stanley
- BrightSphere downgraded to Equal Weight from Overweight at Morgan Stanley
- 10/29/21 Keefe Bruyette
- BrightSphere downgraded to Market Perform from Outperform at Keefe Bruyette
- 04/09/21 BofA
- BrightSphere upgraded to Buy with $27 target at BofA
DIDI Symbol changed to DIDIY - 02/14/22 Bernstein
- Didi initiated with an Outperform at Bernstein
- 07/28/21 Alliance Global Partners
- Alliance Global Partners bullish on Aurora Mobile despite regulatory changes
- 07/28/21 Alliance Global Partners
- iClick Interactive price target lowered to $15 from $21 at Alliance Global
- 07/26/21 Atlantic Equities
- Atlantic Equities downgrades DiDi to Neutral amid active investigations
HZNP Horizon Therapeutics - 01/26/22 Piper Sandler
- Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
- 01/18/22 JPMorgan
- Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
- 12/08/21
- Fly Intel: Top five analyst initiations
- 12/08/21 Wells Fargo
- Horizon Therapeutics initiated with an Overweight at Wells Fargo
- 11/12/21 B. Riley
- Thryv Holdings price target raised to $50 from $45 at B. Riley
- 08/12/21 Baird
- Thryv Holdings price target raised to $46 from $43 at Baird
- 07/23/21 Baird
- Thryv Holdings initiated with an Outperform at Baird
- 07/15/21 B. Riley
- B. Riley starts Thryv with Buy with transition in 'early innings'
- 02/01/22 RBC Capital
- Bausch Health price target lowered to $34 from $40 at RBC Capital
- 11/03/21 JPMorgan
- Bausch Health earnings selloff a buying opportunity, says JPMorgan
- 09/21/21 JPMorgan
- Bausch has 50% upside based on sum-of-the-parts, says JPMorgan
- 08/04/21 JPMorgan
- Bausch Health selloff on Solta IPO plans overdone, says JPMorgan
- 02/07/22 RBC Capital
- NovaGold assumed with a Sector Perform at RBC Capital
- 10/12/21 RBC Capital
- AngloGold Ashanti price target lowered to $16 from $20 at RBC Capital
- 09/13/21 Roth Capital
- Corvus Gold downgraded to Neutral from Buy at Roth Capital
- 07/09/21 Investec
- AngloGold Ashanti upgraded to Hold from Sell at Investec
- 06/02/21 BMO Capital
- AngloGold Ashanti downgraded to Market Perform from Outperform at BMO Capital
- 11/08/21
- Viatris tightens FY21 revenue view to $17.7B-$17.9B from $17.5B-$17.9B
- 11/08/21
- Viatris reports Q3 EPS 26c, consensus 88c
- 11/11/21
- Thryv Holdings reports Q3 EPS 95c, consensus 85c
- 11/03/21
- Tellurian reports Q3 EPS (4c), consensus (4c)
- 11/03/21
- SSR Mining reports Q3 adjusted EPS 40c, consensus 34c
- 11/11/21
- Pretium Resources reports Q3 EPS 13c, consensus 15c
- 01/07/22
- Pacira reported fiscal 2021 preliminary revenue $540.7M-$541.7M
- 11/03/21
- Pacira reports Q3 non-GAAP EPS 72c, consensus 65c
HZNP Horizon Therapeutics - 11/03/21
- Horizon Therapeutics sees FY21 revenue $3.16B-$3.21B, consensus $3.12B
- 11/03/21
- Horizon Therapeutics reports Q3 EPS $1.75, consensus $1.54
DIDI Symbol changed to DIDIY - 12/29/21
- Didi reports Q2 net loss (RMB 24.3B) vs. (RMB 63M) last year
- 10/29/21
- Cerner raises FY21 adjusted EPS view to $3.30 from $3.25, consensus $3.26
- 10/29/21
- Cerner sees Q4 adjusted EPS growth of 10%-13% over Q4 of 2020, consensus 88c
- 10/29/21
- Cerner reports Q3 adjusted EPS 86c, consensus 82c
- 10/28/21
- Notable companies reporting before tomorrow's open
- 02/03/22
- BrightSphere reports Q4 EPS 53c, consensus 38c
- 11/02/21
- Bausch Health backs FY21 revenue view $8.4B-$8.6B, consensus $8.51B
- 11/02/21
- Bausch Health reports Q3 GAAP EPS 52c, consensus $1.29
|